Literature DB >> 24238327

Novel antilisterial bacteriocin licheniocin 50.2 from Bacillus licheniformis VPS50.2 isolated from soil sample.

T Berić1, S Stanković, V Draganić, M Kojić, J Lozo, D Fira.   

Abstract

AIM: To isolate and characterize bacteriocin, licheniocin 50.2, from soil bacteria identified as Bacillus licheniformis. METHODS AND
RESULTS: The strain B. licheniformis VPS50.2 was identified as bacteriocin producer, effective against Gram-positive bacteria, including Listeria monocytogenes, methicillin-resistant Staphylococcus aureus (MRSA) and β-haemolytic streptococci. The start of bacteriocin production coincides with the beginning of sporulation. Ammonium sulfate precipitation, chloroform extraction and ultrafiltration were used for bacteriocin purification. MALDI TOF/TOF mass spectrometry of purified sample detected the protein with molecular mass of 3253·209 Da. N-terminal sequencing recognized first 15 amino acids with the sequence: W E E Y N I I X Q L G N K G Q. We named the newly characterized bacteriocin as subclass II.3 bacteriocin, licheniocin 50·2. The bacteriocin activity was insensitive to lysozyme and proteinase K, heat stable after incubation at 100°C for 30 min and over wide range of pH (2-12). MICs of crude bacteriocin extract were determined for L. monocytogenes and MRSA. Time-kill study showed that licheniocin had bactericidal effect to L. monocytogenes.
CONCLUSION: A novel, thermostable, pH-tolerant bacteriocin active against Gram-positive bacteria was isolated. SIGNIFICANCE AND IMPACT OF THE STUDY: Attributes of new, stable licheniocin 50.2 make it a promising agent for application as biopreservative in food industry.
© 2013 The Society for Applied Microbiology.

Entities:  

Keywords:  Bacillus licheniformis; bacteriocin; licheniocin 50.2; subclass II.3

Mesh:

Substances:

Year:  2013        PMID: 24238327     DOI: 10.1111/jam.12393

Source DB:  PubMed          Journal:  J Appl Microbiol        ISSN: 1364-5072            Impact factor:   3.772


  7 in total

Review 1.  Natural bacterial isolates as an inexhaustible source of new bacteriocins.

Authors:  Jelena Lozo; Ljubisa Topisirovic; Milan Kojic
Journal:  Appl Microbiol Biotechnol       Date:  2021-01-04       Impact factor: 4.813

2.  Antibacterial activity of Bacillus licheniformis B6 against viability and biofilm formation of foodborne pathogens of health importance.

Authors:  Pablo R Díaz; María J Torres; Gabriela Petroselli; Rosa Erra-Balsells; Marcela Carina Audisio
Journal:  World J Microbiol Biotechnol       Date:  2022-08-11       Impact factor: 4.253

3.  Evaluation of antibacterial activity of enterocin A-colicin E1 fusion peptide.

Authors:  Hadis Fathizadeh; Mahmood Saffari; Davoud Esmaeili; Rezvan Moniri; Morteza Salimian
Journal:  Iran J Basic Med Sci       Date:  2020-11       Impact factor: 2.699

4.  Hard surface biocontrol in hospitals using microbial-based cleaning products.

Authors:  Alberta Vandini; Robin Temmerman; Alessia Frabetti; Elisabetta Caselli; Paola Antonioli; Pier Giorgio Balboni; Daniela Platano; Alessio Branchini; Sante Mazzacane
Journal:  PLoS One       Date:  2014-09-26       Impact factor: 3.240

5.  Licheniocin 50.2 and Bacteriocins from Lactococcus lactis subsp. lactis biovar. diacetylactis BGBU1-4 Inhibit Biofilms of Coagulase Negative Staphylococci and Listeria monocytogenes Clinical Isolates.

Authors:  Ivana Cirkovic; Dragana D Bozic; Veselin Draganic; Jelena Lozo; Tanja Beric; Milan Kojic; Biljana Arsic; Eliana Garalejic; Slobodanka Djukic; Slavisa Stankovic
Journal:  PLoS One       Date:  2016-12-08       Impact factor: 3.240

Review 6.  Secretome of Intestinal Bacilli: A Natural Guard against Pathologies.

Authors:  Olga N Ilinskaya; Vera V Ulyanova; Dina R Yarullina; Ilgiz G Gataullin
Journal:  Front Microbiol       Date:  2017-09-01       Impact factor: 5.640

7.  Brevibacillus laterosporus strains BGSP7, BGSP9 and BGSP11 isolated from silage produce broad spectrum multi-antimicrobials.

Authors:  Marija Miljkovic; Sofija Jovanovic; Paula M O'Connor; Nemanja Mirkovic; Branko Jovcic; Brankica Filipic; Miroslav Dinic; David John Studholme; Djordje Fira; Paul D Cotter; Milan Kojic
Journal:  PLoS One       Date:  2019-05-10       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.